As of January 22, 2026, the biosimilar bevacizumab market is identifying as a transformative force in global oncology, with its 2026 valuation contributing to a sector expected to reach $2.23 billion by 2029. The 2026 landscape is defined by a steady CAGR of 7.9%, driven by the expiration of key patents for the reference biologic, Avastin, and a global mandate for cost-effective cancer care....

European biosimilar bevacizumab adoption — the regulatory approval by EMA and subsequent market uptake by national healthcare systems across Germany, France, UK, Italy, Spain, and Scandinavia of multiple biosimilar bevacizumab products beginning in 2017 — creating the most mature and highest-penetration biosimilar bevacizumab market globally and establishing the policy frameworks,...